Free Trial
NASDAQ:GERN

Geron (GERN) Stock Price, News & Analysis

Geron logo
$1.49 +0.04 (+2.76%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$1.51 +0.02 (+1.07%)
As of 05/27/2025 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Geron Stock (NASDAQ:GERN)

Key Stats

Today's Range
$1.42
$1.54
50-Day Range
$1.19
$1.82
52-Week Range
$1.17
$5.34
Volume
11.37 million shs
Average Volume
11.78 million shs
Market Capitalization
$949.01 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.06
Consensus Rating
Moderate Buy

Company Overview

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.

Geron Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
83rd Percentile Overall Score

GERN MarketRank™: 

Geron scored higher than 83% of companies evaluated by MarketBeat, and ranked 170th out of 920 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Geron has received a consensus rating of Moderate Buy. The company's average rating score is 2.78, and is based on 5 buy ratings, 3 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Geron has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Geron's stock forecast and price target.
  • Earnings Growth

    Earnings for Geron are expected to grow in the coming year, from ($0.25) to ($0.07) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Geron is -4.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Geron is -4.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Geron has a P/B Ratio of 3.24. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Geron's valuation and earnings.
  • Percentage of Shares Shorted

    10.03% of the outstanding shares of Geron have been sold short.
  • Short Interest Ratio / Days to Cover

    Geron has a short interest ratio ("days to cover") of 4.2.
  • Change versus previous month

    Short interest in Geron has recently increased by 2.62%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Geron does not currently pay a dividend.

  • Dividend Growth

    Geron does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    10.03% of the outstanding shares of Geron have been sold short.
  • Short Interest Ratio / Days to Cover

    Geron has a short interest ratio ("days to cover") of 4.2.
  • Change versus previous month

    Short interest in Geron has recently increased by 2.62%, indicating that investor sentiment is decreasing.
  • News Sentiment

    Geron has a news sentiment score of 1.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.03 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 11 news articles for Geron this week, compared to 12 articles on an average week.
  • Search Interest

    16 people have searched for GERN on MarketBeat in the last 30 days. This is an increase of 14% compared to the previous 30 days.
  • MarketBeat Follows

    13 people have added Geron to their MarketBeat watchlist in the last 30 days. This is an increase of 225% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Geron insiders have bought more of their company's stock than they have sold. Specifically, they have bought $46,150.00 in company stock and sold $0.00 in company stock.

  • Percentage Held by Insiders

    Only 7.42% of the stock of Geron is held by insiders.

  • Percentage Held by Institutions

    73.71% of the stock of Geron is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Geron's insider trading history.
Receive GERN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Geron and its competitors with MarketBeat's FREE daily newsletter.

GERN Stock News Headlines

Man who predicted $100K Bitcoin sees a huge run coming for another coin …
Sure enough, Bitcoin took off on the exact day Juan said it would. It's up more than 40% since the election … surpassing $100,000 on Dec. 8 .… Now Juan believes it could hit $150,000 … or higher in 2025.
See More Headlines

GERN Stock Analysis - Frequently Asked Questions

Geron's stock was trading at $3.54 at the beginning of 2025. Since then, GERN shares have decreased by 57.9% and is now trading at $1.49.
View the best growth stocks for 2025 here
.

Geron Co. (NASDAQ:GERN) issued its quarterly earnings data on Wednesday, May, 7th. The biopharmaceutical company reported ($0.03) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.04) by $0.01. The firm's revenue was up 12927.3% compared to the same quarter last year.
Read the conference call transcript
.

Top institutional investors of Geron include RA Capital Management L.P. (9.48%), Vanguard Group Inc. (5.36%), Vestal Point Capital LP (3.45%) and Goldman Sachs Group Inc. (1.28%). Insiders that own company stock include Olivia Kyusuk Bloom, Scott Alan Samuels, John A Scarlett, Elizabeth G O'farrell, V Bryan Lawlis, Susan Molineaux, Faye Feller and Andrew J Grethlein.
View institutional ownership trends
.

Shares of GERN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Geron investors own include Meta Platforms (META), NVIDIA (NVDA), Tesla (TSLA), Novavax (NVAX), Advanced Micro Devices (AMD), Intel (INTC) and Bristol-Myers Squibb (BMY).

Company Calendar

Last Earnings
5/07/2025
Today
5/27/2025
Next Earnings (Estimated)
8/14/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:GERN
Employees
70
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$5.06
High Stock Price Target
$9.00
Low Stock Price Target
$1.50
Potential Upside/Downside
+239.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.78
Research Coverage
9 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$184.13 million
Net Margins
-682.48%
Pretax Margin
-682.47%

Debt

Sales & Book Value

Annual Sales
$116.29 million
Price / Cash Flow
N/A
Book Value
$0.46 per share
Price / Book
3.24

Miscellaneous

Free Float
585,761,000
Market Cap
$949.01 million
Optionable
Optionable
Beta
0.76

Social Links

A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for June 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

This page (NASDAQ:GERN) was last updated on 5/28/2025 by MarketBeat.com Staff
From Our Partners